Articles On Phylogica (ASX:PYC)

PYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical programs Orthocell gets first purchase orders The race is hotting up to develop the next RNA-based drug discovery, as a couple of ASX liste...

The ASX 200 will open higher on Tuesday despite another selloff on Wall Street Investors dump risky assets as fears of recession grow FX market in turmoil Local shares are set to open higher on Tuesday. At 8am AEST, the ASX 200 October fu...

Highlights PYC Therapeutics has completed its pharmacokinetic (PK) studies in Non-Human Primates (NHPs) successfully. Results from PK studies will aid the progression of PYC’s investigational drug candidate for evaluation in human bein...

Biotech company PYC Therapeutics (PYC) has increased its stake in Vision Pharma to 93.5 per cent The company has agreed to subscribe to the full $10 million re-capitalisation undertaken by Vision The funds will be used to support Vision’...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

PYC Therapeutics (ASX:PYC) says it has completed a key translational milestone for its RNA platform by determining safe and well-tolerated doses of its co-lead drug candidate in non-human primates.

The hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector from falling today. The ASX 200 finished 0.67% down at 7,420 points. All sectors were down except tech, which gained 0.18%. In contrast, mo...

The ASX 200 Health Index (XHJ) is down by 0.30% at the time of writing, compared to the broader index which is down by 0.50%. Imugene (ASX:IMU) was up 4.35% in morning trading, after announcing partnership agreements  with Merck KGaA and Pf...

The ASX posted steady gains to start the week on Monday, with investors preferences leaning towards tech/consumer stocks and gold (unusual bedfellows) at the expense of the big banks and iron ore majors. Companies that specialise in the pre...

PharmAust has had a busy and productive quarter, setting the foundations for the commercialisation of its lead drug, monepantel. Clinical stage biotech company, PharmAust (ASX:PAA), has had a very productive last quarter, making progress an...

Summary The S&P/ASX200ended 60 points or 0.31% higher at 7,354. The index gained as much as 5% to hit an intraday high of 7,368. The tech sector declined 2.7%, led by BNPL players Afterpay and Zip Co. Australian shares closed...

Summary The S&P/ASX200 traded higher by 20 points or 0.27% at 7,352 by the afternoon. The index opened flat and gained as much 0.5% to hit a high of 7,368. Barring tech, all sectoral indices were trading in green, led by utilities...

The ASX finished in positive territory, although short of an all-time high. The ASX 200 closed 0.15 per cent higher at 7,293 having traded as high as 7,316 in intraday trade. Meanwhile, the ASX Emerging Companies Index retreated 0.40 per ce...

PYC Therapeutics (ASX:PYC), a company developing RNA therapeutics for inherited diseases, has announced it intends to accelerate a key program towards clinical trials.

The ASX 200 close 0.19 per cent lower than Friday at 7,282 points and the ASX Emerging Companies Index fell 0.53 per cent to 2,168 points. Tech shares gaining 2.8 per cent although other sectors were more muted – REITs was the next best per...

The PYC Therapeutics Ltd (ASX: PYC) share price has risen 170% in a year and 13% this month, following promising results in the development of a new lead drug, and the appointment of U.S. Biopharma Executive Jason Haddock to its board. PYC...

PYC Therapeutics (ASX:PYC), a biotechnology company developing precision RNA therapeutics, has announced the appointment of Dr Michael Rosenblatt to its board of directors.

The ASX finished in the red today dragged down by resources and energy. Materials and Energy stocks lost over 1 per cent each while Tech was the best sector gaining 0.70 per cent. Large caps fared worse than small caps with the ASX 200 losi...

Source: GoYong,Shutterstock Summary PYC Therapeutics’ investigational drug, VP-001, has restored function of the Retinal Pigment Epithelium. This achievement differentiates PYC’s RNA approach from Adeno-Associated Virus. PYC’s share...

PYC Therapeutics (ASX:PYC), a biotechnology company developing a new generation of precision RNA therapeutics, has announced the appointment of Dr Glenn Noronha as its chief development officer.

The PYC Therapeutics Ltd (ASX: PYC) share price leapt 9% higher to 18 cents today before slipping to trade at 17 cents by late afternoon. The share price gains came after the company announced that its lead drug was effective in all patien...

S&P Dow Jones Indices has announced the quarterly rebalance of the entire S&P/ASX index hierarchy, revealing which companies have been added and removed. This review of the ASX’s major indices – the S&P/ASX 20, 50, 100, 200, 300...

Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over mi...

Here it is – your weekly look at the stocks fund managers are buying (and selling). Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last week. Substantial shareholders are shareholders holding...

Drug development company, PYC Therapeutics (PYC) has added six new precision medicines to its retinal drug development pipeline These new medicines were developed by Vision Pharma, a subsidiary of PYC, which combines the expertise of PYC a...

PYC Therapeutics (PYC) recently finalised its lead drug molecule in the final quarter of 2019 Its lead drug is a treatment for a type of Retinitis Pigmentosa, which is the main cause of childhood blindness The company is hoping to start th...

There are many reasons why a company might change its name, from being taken over to hiding a shady past. This year 114 companies have changed their name. Family cyber security provider Wangle Technologies became the much more fitting Famil...

Did the doc say to take one pill twice daily, or two tablets once daily? When it comes to correct medication, it’s easy to get it wrong. Because of misreading instructions, forgetfulness, laziness or nasty side effects Australians aren’t es...

Did you know that a hard-working stallion ejaculates 100 times more sperm than the average bloke? Given a virile, but weary, thoroughbred can service hundreds of mares in a breeding season, that’s just as well. But even the most virile of t...

One director has this week put more skin in the game to take his family’s total stake to over $20m — not bad. Nathan Mitchell began with the Mitchell Group in 1989, gradually working his way up the ladder. It is an investment company which...

Ever since the advent of TV, worried parents have cautioned their kids that too much time in front of John Logie Baird’s infernal device will make them go blind – a warning routinely shrugged off by the juvenile couch potatoes. It seems tha...

Biotechnology company Phylogica (ASX: PYC) is one step closer to finding a treatment for the leading cause of childhood blindness, achieving a major milestone in its human ‘retina in a dish’ study. The company today reported results from it...

On Stockhead today: Aussie small caps trying to tackle the opioid crisis, which car manufacturers will survive the EV revolution, Barry FitzGerald looks at upcoming juniors, and how South Australian small caps are putting themselves back on...

A drug delivery platform developed by biotechnology company Phylogica (ASX: PYC) has been shown to be the most effective method of administering anti-sense oligonucleotide (ASO) medications to patients with genetic eye disease. A competitiv...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australia is known to have one of the world’s best health system, which provides quality, safe and reasonable healthcare to individuals. This is the reason which places Australia among the countries with the longest life expectancies in the...

Perth-based biotech company Phylogica (ASX: PYC) has reported positive early stage results from a pilot study of human cells using its proprietary drug delivery technology to create a treatment for blinding genetic eye diseases. The study d...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Biotechnology company Phylogica (ASX: PYC) has unveiled favourable lab results in relation to its time-course studies in animals, with superior performance to current benchmarks officially confirmed. The most recent animal model results als...

Medical tech company Phylogica (ASX: PYC) has cleared an important hurdle in the development of its patented drug delivery platform. The company’s operating focus is on improving the complex procedures used to transmit drugs to the eye. Ear...